16 December 2018
Visiongain has launched a new pharma report Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others.
Demand for RA drugs is on the rise, particularly in developing countries. The TNF inhibitors, which have dominated the market so successfully, are now coming to the end of their patents, opening the way for new biologics and biosimilars to compete for their share of the market. Following the launch of Xeljanz there are other oral DMARDs in development which could potentially undermine the role of the biologics. Changes in the next few years will be critical in determining the future treatment for RA.
The lead analyst of the report commented "one factor driving growth in this market is the discovery of new molecules that are involved in the disease process, hence, new strategies for treating the disease. Molecules such as TNFα, interleukin 6, interleukin 1, and janus kinase have all enabled the development of new treatments to target these molecules.
There are also several restraints on the RA drugs market which discourage the introduction of new drugs. One of these is the increasing pressure from governments to reduce the size of healthcare budgets and restrict the price of drugs. There are also drives to encourage physicians to prescribe generics and biosimilars rather than branded products, and to increase the percentage of patients who receive such products from year to year."
Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi, UCB
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.
19 March 2019
The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.
19 March 2019
With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.
28 February 2019
The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.